Trial Design Articles

Jan 22, 2015
By Applied Clinical Trials
Over recent years global drug companies large or small have recognized that one root cause of the high failure rate in their clinical development lies in the selection of right therapeutic targets.
Jan 19, 2015
Case Study, Trigemina TI-001 for high frequency migraine
Oct 01, 2014
Proving a biosimilar's pharmacokinetic 'equivalence' requires adherence to several unique factors.
Oct 01, 2014
Research shows that the potential of integrated alliances remains elusive in the near term.
Oct 01, 2014
A systematic approach for early identification of BP effects during development of new drugs.
Oct 01, 2014
How modeling and simulation clarified complex exposure levels and an orphan drug got approved.
Jul 29, 2014
Miniaturization of sensors and circuitry has enabled huge proliferation in the development and commercialization of wearable and external monitoring devices for health and wellness.
Jul 01, 2014
Regulatory authorities routinely inspect clinical trials, sites, sponsors, investigators, and other relevant parties to ensure compliance with good clinical practice guidelines.
Jul 01, 2014
Objective internal monitoring can help clinical trial sponsors transform a regulatory mandate into a valuable quality improvement tool.

Trial Design News

PHT Offers Rater Training in Three Instruments

The pharmaceutical industry is further optimizing the collection of high quality electronic patient reported outcomes (ePROs) data for clinical research, with PHT Corporation Rater Training programs

Covance Solution Bridges Preclinical to Clinical Development

Covance Inc., the world’s most comprehensive drug development company, today announced the introduction of Covance Early Phase Development Solutions,

Novella Clinical Partners with Academia on CV Clinical Trials Services

Novella Clinical and the Cardiovascular Research Foundation announced a preferred provider collaboration.

Almac Releases ePRO Data

Almac announced the results of a survey conducted by researchers at the Tufts Center for the Study of Drug Development.

Mapi Group Acquires Select Services of Optum Life Sciences

Mapi has completed the acquisition of select Optum Life Sciences services.